Carl Zeiss Meditec AG (VIE:AFX)
Austria · Delayed Price · Currency is EUR | Market Cap | 2.17B -61.2% |
| Revenue (ttm) | 2.20B +5.9% |
| Net Income | 120.61M -23.2% |
| EPS | 1.40 -21.2% |
| Shares Out | n/a |
| PE Ratio | 18.03 |
| Forward PE | 15.42 |
| Dividend | 0.55 (2.24%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Average Volume | 33 |
| Open | 24.62 |
| Previous Close | 24.90 |
| Day's Range | 24.60 - 24.78 |
| 52-Week Range | 22.82 - 65.65 |
| Beta | n/a |
| RSI | 46.75 |
| Earnings Date | May 12, 2026 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]
Financial Performance
In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.
Financial StatementsNews
Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...